ABSTRACT
Testicular tumours, of which the vast majority are of germ cell origin, are an important group of neoplasms, as the majority are curable. The management of testicular cancer has been a major oncological success story and provides a model for the management of curative solid tumours. In recent years, attention has focused not only on improving cure rates in patients where treatment has historically been unsuccessful but also on optimizing treatment for good prognosis groups with the aim of limiting long-term adverse effects of treatment.
